Search in the Abstract Database

Search Abstracts 2011

* = Presenting author

P129. Evaluation of fecal calprotectin level in patients with chronic inflammatory bowel diseases

Y. Stepanov, N. Fyodorova

Dniepropetrovsk State Medical Academy, Dniepropetrovsk, Ukraine

According to conventional standard endoscopic and morphological methods play the leading role in diagnosis of bowel diseases. But performing them is associated with some difficulties including preparation of patient and procedure complexity. Besides using endoscopy not always reveals inflammation especially if it localizes in small intestine. That is why the actual question is search of new methodics which does not have indicated drawbacks but have the same high diagnostic accuracy.

Aim of study: To compare the diagnostic accuracy of evaluation of fecal calprotectin (FC) level and endoscopic and morphological methods in diagnosis of chronic inflammatory bowel diseases (CIBD).

Materials and Methods: 111 patients were involved in the investigation. They were divided into 3 groups: group 1 – patients with ulcerative colitis (UC) (n = 48); group 2 – patients with Crohn's diseases (CD) (n = 32); group 3 (control) – healthy persons (n = 31). In all the patients there were established the preliminary diagnosis according to examination standard and there was performed the endoscopic examination with further morphological examination. Bowel mucosa changes were estimated using the conventional classifications. Age of patients was 18–67 years, women were 73 (45.6%) persons, men were 87 (54.4%) persons. In all the patients FC level were measured using immune-enzyme method. Test-sets of BUHLMANN (Switzerland) were used.

Results: There was revealed the significant link between endoscopic and morphological evaluation of bowel inflammation severity and received FC levels in patients with CIBD (r = 0.65; CI 0.48–0.75; p < 0.001). FC levels in patients with 0 and 1 degrees of endoscopic activity did not differ significantly from FC level of persons in control group and were 20.07±7.08 mcg/g and 22.34±7.67 mcg/g, though the dependence between these two levels was interpreted as tendency to increase of the parameter (p > 0.1). FC levels of patients with 2 and 3 severity of endoscopic activity evidently (p < 0.01) differed from mean FC level of healthy persons and were 67.18±7.48 mcg/g and 95.18±4.70 mcg/g accordingly.

Conclusion: Fecal calprotectin level in patients with CIBD was evidently higher than in control group and correlated markedly with inflammation activity which was established using endoscopic and morphological criteria. This gives the ground for using FC level for diagnosis of bowel inflammation.